NCT04498390View on ClinicalTrials.gov

A Safety Study of LY3493269 in Healthy Participants

PHASE1CompletedINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

September 3, 2020

Primary Completion Date

December 28, 2020

Study Completion Date

December 28, 2020

Conditions
Healthy
Interventions
DRUG

LY3493269

Administered orally.

DRUG

Placebo

Administered orally.

Trial Locations (1)

138623

Lilly Centre for Clinical Pharmacology, Singapore

All Listed Sponsors
lead

Eli Lilly and Company

INDUSTRY

NCT04498390 - A Safety Study of LY3493269 in Healthy Participants | Biotech Hunter | Biotech Hunter